Battle of oral anticoagulants in the field of atrial fibrillation scrutinized from a clinical practice (the real world) perspective

被引：17

作者：

Altman R. ^{[1
]}

Vidal H.O. ^{[2
]}

机构：

[1] Centro de Trombosis de Buenos Aires, 1056 Buenos Aires

[2] Hospital Italiano de La Plata, Area de Hematología, Sección Hemostasia y Trombosis, Buenos Aires, 1900 La Plata, Pcia. de

来源：

Thrombosis Journal | / 9卷 / 1期

关键词：

Antiplatelet drugs; Apixaban; Aspirin; Atrial fibrillation; Dabigatran; Oral anticoagulants; Rivaroxaban;

D O I：

10.1186/1477-9560-9-12

中图分类号：

学科分类号：

摘要：

Warfarin has a long history of benefit and has become the gold standard medication for the prevention of ischemic stroke in patients with atrial fibrillation. Nevertheless, it is far from perfect and there is no doubt that new drugs must be found to replace warfarin. The new oral anticoagulants that are on the market or awaiting approval or under research offer some benefits but not enough to replace warfarin until results of additional studies can show an adequate balance between effectiveness/safety and cost/benefit. There are several issues concerning the new oral anticoagulants. It is essential that the effect of any anticoagulant can be measured in plasma. But to date, there is no test to assess the effect or therapeutic range for the new oral anticoagulants. There is no antidote to neutralize the action of the new drugs in cases of bleeding or when acute surgical intervention is necessary. Dabigatran requires dose adjustment in patients with moderate renal impairment and is contraindicated in patients with severe renal failure. Rivaroxaban should be used with caution in patients with severe renal impairment. Apixaban excretion is also partly dependent on renal function, although the impact of renal insufficiency has not yet been determined. How anticoagulant bridging can be done before surgery has not yet been established. In conclusion, although thousands of patients have been treated in phase III studies, additional data are necessary before conclusions can be drawn on the potential for these new anticoagulant drugs to replace warfarin in patients with atrial fibrillation. © 2011 Altman and Vidal; licensee BioMed Central Ltd.

引用

共 32 条

[21]

Yusuf S., Mehta S.R., Chrolavicius S., Afzal R., Pogue J., Granger C.B., Budaj A., Peters R.J., Bassand J.P., Wallentin L., Joyner C., Fox K.A., Comparison of fondaparinux and enoxaparin in acute coronary syndromes, N Engl J Med, 354, pp. 1464-1476, (2006)

[22]

Eikelboom J.W., Wallentin L., Connolly S.J., Ezekowitz M., Healey J.S., Oldgren J., Yang S., Alings M., Kaatz S., Hohnloser S.H., Diener H.C., Franzosi M.G., Huber K., Reilly P., Varrone J., Yusuf S., Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) trial, Circulation, 123, pp. 2363-2372, (2011)

[23]

Rivaroxaban-once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation: rationale and design of the ROCKET AF study, Am Heart J, 159, (2010)

[24]

Cohen A.T., Spiro T.E., Buller H.R., Haskell L., Hu D., Hull R., Mebazaa A., Merli G., Schellong S., Spyropoulos A., Tapson V., Extended-duration rivaroxaban thromboprophylaxis in acutely ill medical patients: MAGELLAN study protocol, J Thromb Thrombolysis, 31, pp. 407-416, (2011)

[25]

Lopes R.D., Alexander J.H., Al-Khatib S.M., Ansell J., Diaz R., Easton J.D., Gersh B.J., Granger C.B., Hanna M., Horowitz J., Hylek E.M., McMurray J.J., Verheugt F.W., Wallentin L., Apixaban for reduction in stroke and other thromboembolic events in atrial fibrillation (ARISTOTLE) trial: design and rationale, Am Heart J, 159, pp. 331-339, (2010)

[26]

Alexander J.H., Lopes R.D., James S., Rakhi Kilaru R., He Y., Mohan P., Bhatt D.L., Goodman S., Verheugt F.W., Flather M., Huber K., Liaw D., Husted S.E., Lopez-Sendon J., De Caterina R., Jansky P., Darius H., Vinereanu D., Cornel J.H., Cools F., Atar D., Leiva-Pons J.L., Keltai M., Ogawa H., Pais P., Parkhomenko A., Ruzyllo W., Diaz R., White H., Ruda M., Geraldes M., Lawrence J., Harrington R.A., Wallentin L., Apixaban with antiplatelet therapy after acute coronary syndrome, N Engl J Med, (20

[27]

Lip G.Y., Frison L., Halperin J.L., Lane D.A., Comparative validation of a novel risk score for predicting bleeding risk in anticoagulated patients with atrial fibrillation: the HAS-BLED (Hypertension, Abnormal Renal/Liver Function, Stroke, Bleeding History or Predisposition, Labile INR, Elderly, Drugs/Alcohol Concomitantly) score, J Am Coll Cardiol, 57, pp. 173-180, (2011)

[28]

Gibson C.M., Mega J.L., Burton P., Goto S., Verheugt F., Bode C., Plotnikov A., Sun X., Cook-Bruns N., Braunwald E., Rationale and design of the Anti-Xa Therapy to Lower cardiovascular events in Addition to standard therapy in Subjects with Acute Coronary Syndrome-Thrombolysis in Myocardial Infarction 51 (ATLAS-ACS 2 TIMI 51) trial: a randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of rivaroxaban in subjects with acute coronary syndrome, Am Heart J, 161, p

[29]

Hansen M.L., Sorensen R., Clausen M.T., Fog-Petersen M.L., Raunso J., Gadsboll N., Gislason G.H., Folke F., Andersen S.S., Schramm T.K., Abildstrom S.Z., Poulsen H.E., Kober L., Torp-Pedersen C., Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation, Arch Intern Med, 170, pp. 1433-1441, (2010)

[30]

Garcia L.A., Lin K.J., Hernandez-Diaz S., Johansson S., Risk of upper gastrointestinal bleeding with low-dose acetylsalicylic acid alone and in combination with clopidogrel and other medications, Circulation, 123, pp. 1108-1115, (2011)

← 1 2 3 4 →